Atara Biotherapeutics (NASDAQ:ATRA) Announces Earnings Results

Atara Biotherapeutics (NASDAQ:ATRA) posted its quarterly earnings results on Tuesday. The biotechnology company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.04, FiscalAI reports. The firm had revenue of $0.52 million for the quarter, compared to analyst estimates of $2.90 million. Atara Biotherapeutics had a negative return on equity of 79.12% and a negative net margin of 40.91%.

Atara Biotherapeutics Price Performance

Atara Biotherapeutics stock traded down $0.82 during mid-day trading on Thursday, reaching $9.66. 252,588 shares of the company were exchanged, compared to its average volume of 1,219,290. The firm has a market cap of $82.21 million, a PE ratio of -14.42 and a beta of -0.30. The company has a fifty day simple moving average of $5.59 and a 200-day simple moving average of $9.15. Atara Biotherapeutics has a 12 month low of $3.92 and a 12 month high of $19.15.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Weiss Ratings restated a “sell (d)” rating on shares of Atara Biotherapeutics in a report on Friday, March 27th. Wall Street Zen lowered Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Finally, Canaccord Genuity Group set a $13.00 target price on Atara Biotherapeutics and gave the stock a “buy” rating in a report on Friday, May 8th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $9.50.

Insider Activity

In related news, major shareholder Innovation Ltd Panacea sold 313,446 shares of the firm’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $10.10, for a total value of $3,165,804.60. Following the transaction, the insider owned 1,011,000 shares in the company, valued at approximately $10,211,100. This trade represents a 23.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 41.20% of the company’s stock.

Institutional Investors Weigh In On Atara Biotherapeutics

A number of large investors have recently bought and sold shares of the company. Quadrature Capital Ltd lifted its holdings in shares of Atara Biotherapeutics by 22.8% during the 4th quarter. Quadrature Capital Ltd now owns 20,321 shares of the biotechnology company’s stock worth $368,000 after acquiring an additional 3,779 shares during the period. Bridgeway Capital Management LLC increased its stake in Atara Biotherapeutics by 133.5% in the fourth quarter. Bridgeway Capital Management LLC now owns 32,691 shares of the biotechnology company’s stock valued at $591,000 after acquiring an additional 18,691 shares during the last quarter. Marshall Wace LLP raised its position in Atara Biotherapeutics by 28.4% during the fourth quarter. Marshall Wace LLP now owns 148,632 shares of the biotechnology company’s stock valued at $2,689,000 after purchasing an additional 32,836 shares in the last quarter. Walleye Capital LLC acquired a new position in Atara Biotherapeutics during the fourth quarter valued at approximately $220,000. Finally, Renaissance Technologies LLC lifted its stake in Atara Biotherapeutics by 58.6% during the fourth quarter. Renaissance Technologies LLC now owns 30,040 shares of the biotechnology company’s stock worth $543,000 after purchasing an additional 11,104 shares during the last quarter. 70.90% of the stock is currently owned by institutional investors and hedge funds.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders.

The company’s lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers.